TRIALS OF THERAPIES FOR PRIMARY BILLIARY CIRRHOSIS

摘要原发性胆汁性肝硬变是一种病因不明的疾病。 以慢性进行性肝内胆汁淤积为特征 非化脓性肝内小胆管破坏。因为有些人 其他自身免疫性疾病似乎对某些 免疫抑制药物，选定的免疫抑制药物的试验 在有症状的PBC患者中进行。在随机化的 百菌清治疗的对照试验，用该药治疗 随着血清胆红素升高率的降低， 升高的血清IgM水平正常化和改善 肝活检组织中的炎性细胞浸润。这些发现有 促使人们寻找更安全、更有效的免疫抑制药物 比氯氨丁酚致癌潜力小。10名PBC患者有 已经进入了甲氨蝶呤治疗的公开试验，并正在耐受 药吃得很好。

Primary binary cirrhosis (PBC) is a disease of unknown etiology characterized by slowly progressive intrahepatic cholestasis due to non-suppurative, destruction of small intrahepatic bile ducts. Because some other autoimmune diseases appear to respond favorably to certain immunosuppressive agents, trials of selected immunosuppressive drugs are being undertaken in patients with symptomatic PBC. In a randomized controlled trial of chlorambucil therapy, treatment with the drug was associated with a decrease in the rate of increase of serum bilirubin, normalization of elevated serum IgM levels and an improvement in inflammatory cell infiltration in liver biopsies. These findings have prompted a search for safer and more effective immunosuppressive drugs with less carcinogenic potential than chlorambucol. Ten patients with PBC have been entered into an open trial of methotrexate therapy and are tolerating the drug well.